Opinion|Videos|December 17, 2024
Testing Methodologies and Standards in Metastatic NSCLC
Author(s)Heather A. Wakelee, MD, FASCO, Jacob Sands, MD
Panelists discuss the various tests available for detecting genetic mutations in advanced non–small cell lung cancer (NSCLC), including next-generation sequencing (NGS), reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and Sanger sequencing, and explore whether one method is considered the “gold standard” according to the NCCN guidelines. They also address the appropriate use of circulating tumor DNA (ctDNA) testing, comparing it to tissue testing in this disease state.
Advertisement
Episodes in this series
- Dr Sands to Dr Wakelee: What tests are available for detecting genetic mutations (ie, NGS, RT-PCR, FISH, IHC, Sanger, etc) in advanced NSCLC?
- Is one considered the “gold standard” or preferred compared with the others?
NCCN Guidelines Version 10.2024 Non-Small Cell Lung Cancer - Dr. Wakelee: Describe when circulating tumor DNA (ctDNA) testing is appropriate.
- How does it compare to tissue testing in this disease state?
Advertisement
Related to this article
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Davide Melisi, MD, PhD, discusses INCB161734’s mechanism of action and the DAWN-303 trial design in KRAS G12D-mutated pancreatic cancer.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Advertisement
Advertisement
Trending on OncLive
1
INCB161734 Combination Data Shape DAWN-303’s All-Comers Design in Frontline KRAS G12D-Mutated PDAC
2
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC
3
Fox Chase Cancer Center Researchers Identify Potential New Target for Pancreatic Cancer
4
Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
5